Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Audio By Carbonatix

FREMONT, Calif.--(BUSINESS WIRE)--Aug 7, 2025--

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET.

Teleconference Details:
Toll Free: 877-545-0523
International: 973-528-0016
Participant Access Code: 793820

Webcast Link
https://www.webcaster4.com/Webcast/Page/2865/52776

About Tivic Health Systems, Inc.

Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients’ immune system. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ under development for the treatment of acute radiation syndrome (ARS), has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases.

Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https://ir.tivichealth.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks anduncertainties. All statements, other than statements of historical fact, contained in this press release areforward-looking statements. Forward-looking statements contained in this press release may beidentified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,”“should,” “will,” “would,” or the negative of these words or other similar expressions, although not allforward-looking statements contain these words. Forward-looking statements are based on Tivic HealthSystems Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptionsthat are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading “Risk Factors”, as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.  

View source version on businesswire.com:https://www.businesswire.com/news/home/20250807220520/en/

CONTACT: Investor Contact:

Hanover International, Inc.

[email protected] Contact:

Deanne Eagle or Laura Min Jackson

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Tivic Health® Systems, Inc.

Copyright Business Wire 2025.

PUB: 08/07/2025 08:30 AM/DISC: 08/07/2025 08:29 AM

http://www.businesswire.com/news/home/20250807220520/en